How do I install the Ata Ppgl Genetic Marker Interpretation For Mets skill?

Run npx skillmds@latest add dromlakhani/ata-ppgl-genetic-marker-interpretation-for-mets in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Is Ata Ppgl Genetic Marker Interpretation For Mets safe to use?

This skill has not completed SkillMD's automated safety review yet. Independent scanners report: SkillSpector: PASS, Skill Scanner: PASS. Capability flags: docs only. SkillMD never runs a skill's scripts for you; review the SKILL.md before installing.

Which AI agents work with Ata Ppgl Genetic Marker Interpretation For Mets?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Is Ata Ppgl Genetic Marker Interpretation For Mets free to use?

Yes. Installing skills from SkillMD is free, and the skill stays under its author's original license.

Who published Ata Ppgl Genetic Marker Interpretation For Mets?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Ata Ppgl Genetic Marker Interpretation For Mets by dromlakhani

Name: Ata Ppgl Genetic Marker Interpretation For Mets
Rating: 4.666666666666667 (3 reviews)
Author: dromlakhani

Ata Ppgl Genetic Marker Interpretation For Mets

This skill interprets SDHx and fumarate hydratase gene variants to assess metastasis risk in pheochromocytoma and paraganglioma patients. Triggered by identification of SDHB pathogenic variant (or negative SDHB immunostaining), FH variant, or other SDHx mutations when a clinician asks how genetic results affect metastasis risk assessment.

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

Interpret genetic markers for metastasis risk in pheochromocytoma and paraganglioma

STEP 1 — Gather Information

Collect genetic test results (SDHx, FH, SDHB), SDHB immunostaining status, tumor size, necrosis, vascular invasion, S100 expression, catecholamine phenotype (adrenergic/noradrenergic), age at diagnosis, and tumor location (adrenal vs extra-adrenal).

STEP 2 — Rule In / Rule Out

If a pathogenic SDHB variant is present or SDHB immunostaining is negative, rule in high metastasis risk; otherwise, rule out high risk based solely on SDHB and proceed to COPPS scoring.

STEP 3 — Classify or Stratify

For SDHB-positive cases, classify as high metastasis risk (35‑75%); for SDHB‑negative cases, calculate the COPPS score (tumor size, necrosis, vascular invasion, S100 loss, SDHB immunostaining) and stratify risk as low (0‑1), intermediate (2), or high (≥3).

STEP 4 — Decide

If high risk (SDHB variant or COPPS ≥3), initiate intensified surveillance (imaging every 6‑12 months, genetic counseling, discuss prophylactic interventions); if low/intermediate risk, follow standard postoperative surveillance (annual biochemical testing and imaging).

Clinical Guardrails / Mimics / Pitfalls

Do not rely exclusively on SDHB immunostaining without confirmatory genetic testing; FH variants confer risk but data are limited; avoid missing metastatic PPGL in SDHB‑negative cases by neglecting tumor size, necrosis, or catecholamine phenotype; do not substitute genetic testing for clinical follow‑up in young patients with large tumors.

Concrete Clinical Example

A 45‑year‑old patient with an extra‑adrenal PGL (5 cm) undergoes genetic testing and is found to harbor an SDHB pathogenic variant; SDHB immunostaining is negative. The lesion shows necrosis. Based on the SDHB variant, the patient is classified as high metastasis risk and is scheduled for 6‑monthly 18F‑FDG PET/CT and annual MRI, with referral for genetic counseling.

Source: Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025, Japan Endocrine Society, 2025, DOI:10.1507/endocrj.EJ25-0165

---name: ata-ppgl-genetic-marker-interpretation-for-metsdescription: This skill interprets SDHx and fumarate hydratase gene variants to assess metastasis risk in pheochromocytoma and paraganglioma patients. Triggered by identification of SDHB pathogenic variant (or negative SDHB immunostaining), FH variant, or other SDHx mutations when a clinician asks how genetic results affect metastasis risk assessment.---# Interpret genetic markers for metastasis risk in pheochromocytoma and paraganglioma## STEP 1 — Gather InformationCollect genetic test results (SDHx, FH, SDHB), SDHB immunostaining status, tumor size, necrosis, vascular invasion, S100 expression, catecholamine phenotype (adrenergic/noradrenergic), age at diagnosis, and tumor location (adrenal vs extra-adrenal).## STEP 2 — Rule In / Rule OutIf a pathogenic SDHB variant is present or SDHB immunostaining is negative, rule in high metastasis risk; otherwise, rule out high risk based solely on SDHB and proceed to COPPS scoring.## STEP 3 — Classify or StratifyFor SDHB-positive cases, classify as high metastasis risk (35‑75%); for SDHB‑negative cases, calculate the COPPS score (tumor size, necrosis, vascular invasion, S100 loss, SDHB immunostaining) and stratify risk as low (0‑1), intermediate (2), or high (≥3).## STEP 4 — DecideIf high risk (SDHB variant or COPPS ≥3), initiate intensified surveillance (imaging every 6‑12 months, genetic counseling, discuss prophylactic interventions); if low/intermediate risk, follow standard postoperative surveillance (annual biochemical testing and imaging).## Clinical Guardrails / Mimics / PitfallsDo not rely exclusively on SDHB immunostaining without confirmatory genetic testing; FH variants confer risk but data are limited; avoid missing metastatic PPGL in SDHB‑negative cases by neglecting tumor size, necrosis, or catecholamine phenotype; do not substitute genetic testing for clinical follow‑up in young patients with large tumors.## Concrete Clinical ExampleA 45‑year‑old patient with an extra‑adrenal PGL (5 cm) undergoes genetic testing and is found to harbor an SDHB pathogenic variant; SDHB immunostaining is negative. The lesion shows necrosis. Based on the SDHB variant, the patient is classified as high metastasis risk and is scheduled for 6‑monthly 18F‑FDG PET/CT and annual MRI, with referral for genetic counseling.**Source:** Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025, Japan Endocrine Society, 2025, DOI:10.1507/endocrj.EJ25-0165

Frequently asked questions